This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(10)
- Annex to CHMP highlights(0)
- Annual Report(2)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Full risk management plan(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(1)
- Newsletter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(6)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(54)
- Press Release(8)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(2)
- Report(6)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(1)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(1)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- (-)Brexit(121)
- Careers(5)
- Clinical trials(599)
- Compassionate use(17)
- Compliance and inspections(600)
- Corporate(115)
- COVID-19(899)
- Data on medicines(987)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2185)
- Governance(707)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(47008)
- Medicines for use outside the EU(148)
- Medicine shortages(299)
- Mpox(39)
- Paediatrics(12241)
- Parallel distribution(15)
- Pharmacovigilance(9660)
- Procurement(132)
- Product information(6315)
- Quality of medicines(222)
- Rare diseases(8242)
- Referrals(3388)
- Regulatory and procedural guidance(3520)
- Research and development(495)
- Scientific advice(290)
- Scientific guidelines(1753)
- SME(259)
- Vaccines(1501)
- Veterinary limited markets(64)
Search results (121)
The European Medicines Agency (EMA) and the European Commission have been providing guidance to help pharmaceutical companies prepare for the consequences of Brexit since 2017. This includes companies responsible for human medicines and for veterinary medicines, both centrally and nationally authorised.
2020 annual report of the European Medicines Agency
English (EN) (7.46 MB - PDF)
Questions and answers to stakeholders on the implementation of the protocol on Ireland / Northern Ireland
English (EN) (315.19 KB - PDF)
Report of industry stakeholders webinar on the UK withdrawal from the European Union - End of transition period
English (EN) (287.01 KB - PDF)
Joint industry presentation - Industry stakeholders webinar on the UK withdrawal from the European Union
English (EN) (362.22 KB - PDF)
Presentation - Updates on the Ireland and Northern Ireland Protocol implementation (Zigmars Sebris)
English (EN) (450.44 KB - PDF)
Presentation - EMA operational and procedural preparedness update (Alberto Ganan Jimenez)
English (EN) (456.71 KB - PDF)
Agenda - Industry stakeholders webinar on the UK withdrawal from the European Union - End of transition period
English (EN) (105.34 KB - PDF)